Analysts predict that Bruker Co. (NASDAQ:BRKR) will report sales of $477.29 million for the current quarter, according to Zacks. Four analysts have made estimates for Bruker’s earnings, with the highest sales estimate coming in at $481.68 million and the lowest estimate coming in at $475.30 million. Bruker reported sales of $443.70 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.6%. The company is scheduled to issue its next earnings report on Thursday, August 1st.
On average, analysts expect that Bruker will report full year sales of $2.04 billion for the current fiscal year, with estimates ranging from $2.03 billion to $2.04 billion. For the next financial year, analysts anticipate that the company will post sales of $2.14 billion, with estimates ranging from $2.12 billion to $2.17 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Bruker.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.24 by $0.04. The firm had revenue of $461.40 million for the quarter, compared to analyst estimates of $450.46 million. Bruker had a return on equity of 26.28% and a net margin of 9.53%. Bruker’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.24 earnings per share.
Several equities analysts have issued reports on BRKR shares. Svb Leerink reaffirmed an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. Zacks Investment Research lowered Great Portland Estates from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Wolfe Research started coverage on Waters in a report on Thursday, May 30th. They set an “underperform” rating on the stock. Deutsche Bank raised their price objective on Prudential Financial from $97.00 to $104.00 and gave the stock a “hold” rating in a report on Friday, April 12th. Finally, Barclays reaffirmed an “overweight” rating and set a GBX 310 ($4.05) price objective on shares of in a report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $48.18.
In related news, CEO Frank H. Laukien sold 400,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $41.48, for a total value of $16,592,000.00. Following the completion of the sale, the chief executive officer now owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Marc A. Kastner sold 1,374 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total transaction of $57,419.46. Following the completion of the sale, the director now owns 10,811 shares of the company’s stock, valued at approximately $451,791.69. The disclosure for this sale can be found here. Insiders have sold 801,374 shares of company stock valued at $33,241,419 in the last quarter. Insiders own 26.50% of the company’s stock.
A number of large investors have recently made changes to their positions in BRKR. Comerica Bank acquired a new stake in Bruker in the fourth quarter valued at about $219,000. LPL Financial LLC lifted its position in Bruker by 25.7% in the fourth quarter. LPL Financial LLC now owns 34,133 shares of the medical research company’s stock valued at $1,016,000 after purchasing an additional 6,972 shares during the period. BlackRock Inc. lifted its position in Bruker by 2.6% in the fourth quarter. BlackRock Inc. now owns 5,465,722 shares of the medical research company’s stock valued at $162,713,000 after purchasing an additional 139,004 shares during the period. Raymond James & Associates lifted its position in Bruker by 16.1% in the fourth quarter. Raymond James & Associates now owns 15,370 shares of the medical research company’s stock valued at $458,000 after purchasing an additional 2,128 shares during the period. Finally, Northern Trust Corp lifted its position in Bruker by 14.3% in the fourth quarter. Northern Trust Corp now owns 633,484 shares of the medical research company’s stock valued at $18,859,000 after purchasing an additional 79,482 shares during the period. Hedge funds and other institutional investors own 66.73% of the company’s stock.
Shares of BRKR stock traded down $0.17 during mid-day trading on Monday, hitting $48.35. 1,125,328 shares of the stock were exchanged, compared to its average volume of 666,667. The firm’s fifty day moving average price is $47.48. The company has a market capitalization of $7.61 billion, a PE ratio of 34.54, a price-to-earnings-growth ratio of 2.38 and a beta of 1.32. Bruker has a 12-month low of $26.10 and a 12-month high of $51.41. The company has a quick ratio of 1.27, a current ratio of 2.12 and a debt-to-equity ratio of 0.42.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 21st. Stockholders of record on Monday, June 3rd were paid a dividend of $0.04 per share. The ex-dividend date of this dividend was Friday, May 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.33%. Bruker’s dividend payout ratio (DPR) is 11.43%.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.